The Misuse of Drugs Act 1971 (Modification) Order 2003
At the Court at Buckingham Palace, the 8th day of May 2003
Present,
The Queen’s Most Excellent Majesty in Council
Whereas a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and has been approved by a resolution of each House of Parliament;
1.
This Order shall be cited as the Misuse of Drugs Act 1971 (Modification) Order 2003 and shall come into force on 1st July 2003.
2.
(1)
(2)
In paragraph 1(a) of Part I of that Schedule there shall be inserted—
(a)
after “Dihydrocodeinone O-carboxymethyloxime”, “Dihydroetorphine”; and
(b)
after “Racemorphan”, “Remifentanil.”.
(3)
In paragraph 1(a) of Part III of that Schedule, there shall be inserted—
(a)
after “Haloxazolam”, “4-Hydroxy-n-butyric acid”; and
(b)
after “N-Ethylamphetamine”, “Zolpidem”.
(4)
In paragraph 1(b) of Part III of that Schedule, there shall be inserted—
(a)
before “Atamestane”, “4-Androstene-3, 17-dione” and “5-Androstene-3, 17-diol”; and
(b)
after “Nandrolone”, “19-Nor-4-Androstene-3, 17-dione”; and “19-Nor-5-Androstene-3, 17-diol”.
This Order adds eight substances to Schedule 2 to the Misuse of Drugs Act 1971 which specifies drugs which are subject to control under the Act. Two of the substances, Dihydroetorphine and Remifentanil, are added as Class A drugs; and the remaining six, 4-Androstene-3, 17-dione; 5-Androstene-3, 17-diol; 4-Hydroxy-n-butyric acid; 19-Nor-4-Androstene-3; 17-dione, 19-Nor-5-Androstene-3, 17-diol and Zolpidem, are added as Class C drugs.